Published in Blood on April 22, 2009
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) (2011) 2.21
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood (2010) 2.21
Advances in understanding benzene health effects and susceptibility. Annu Rev Public Health (2010) 1.77
An update of cancer incidence in the Agricultural Health Study. J Occup Environ Med (2010) 1.44
Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc (2010) 1.11
Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc (2010) 1.09
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
The relationship between multiple myeloma and occupational exposure to six chlorinated solvents. Occup Environ Med (2010) 0.95
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood (2011) 0.93
The significance of monoclonal gammopathy of undetermined significance. Haematologica (2009) 0.88
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia (2014) 0.88
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood (2011) 0.86
Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomarkers Prev (2013) 0.84
Discovering the meaning of monoclonal gammopathy of undetermined significance: current knowledge, future challenges. Transl Med UniSa (2014) 0.82
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Curr Hematol Malig Rep (2010) 0.82
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol (2010) 0.78
Multiple Myeloma and lifetime occupation: results from the EPILYMPH study. J Occup Med Toxicol (2012) 0.78
Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers. J Environ Sci Health B (2016) 0.75
Prevalence and type of monoclonal gammopathy of undetermined significance in an apparently healthy Nigerian population: a cross sectional study. BMC Blood Disord (2012) 0.75
Robert Arthur Kyle, MD: a conversation with the editor. Proc (Bayl Univ Med Cent) (2010) 0.75
Investing in prospective cohorts for etiologic study of occupational exposures. Am J Ind Med (2015) 0.75
History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. Ann Hematol (2016) 0.75
The Biomarkers of Exposure and Effect in Agriculture (BEEA) Study: Rationale, Design, Methods, and Participant Characteristics. J Toxicol Environ Health A (2015) 0.75
A case of multiple myeloma in a poultry worker. Ann Occup Environ Med (2014) 0.75
Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome. Case Rep Genet (2011) 0.75
Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset. J Cancer Res Clin Oncol (2015) 0.75
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Multiple myeloma. N Engl J Med (2004) 10.81
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
The Agricultural Health Study. Environ Health Perspect (1996) 5.72
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from Iowa. Epidemiology (2002) 3.00
Clues to cancer etiology from studies of farmers. Scand J Work Environ Health (1992) 2.98
Health effects of chronic pesticide exposure: cancer and neurotoxicity. Annu Rev Public Health (2004) 2.35
Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study. Environ Health Perspect (2005) 2.05
Occupational and other environmental factors and multiple myeloma: a population based case-control study. Br J Ind Med (1992) 1.74
Proportionate mortality of crop and livestock farmers in the United States, 1984-1993. Am J Ind Med (2002) 1.44
Cancer and other causes of death among male and female farmers from twenty-three states. Am J Ind Med (1993) 1.40
Cancer incidence in the agricultural health study. Scand J Work Environ Health (2005) 1.39
A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Int J Cancer (1989) 1.28
Cancer mortality among Iowa farmers: recent results, time trends, and lifestyle factors (United States). Cancer Causes Control (1998) 1.22
Multiple myeloma--a case-control study. Br J Cancer (1988) 1.20
Cancer incidence among pesticide applicators exposed to atrazine in the Agricultural Health Study. J Natl Cancer Inst (2004) 1.19
Meta-analyses of multiple myeloma and farming. Am J Ind Med (1997) 1.19
Epidemiologic studies of cancer in agricultural workers. Am J Ind Med (1990) 1.19
Occupation and lymphoid neoplasms. Br J Cancer (1989) 1.15
Cancer incidence among pesticide applicators exposed to chlorpyrifos in the Agricultural Health Study. J Natl Cancer Inst (2004) 1.14
Occupation, pesticide exposure and risk of multiple myeloma. Scand J Work Environ Health (2004) 1.10
Cancer incidence among pesticide applicators exposed to permethrin in the Agricultural Health Study. Environ Health Perspect (2008) 1.09
Cancer risks among Missouri farmers. Cancer (1989) 1.09
Cancer in Iowa farmers: recent results. Am J Ind Med (1990) 1.08
Farming and mortality from multiple myeloma: a case-control study with the use of death certificates. J Natl Cancer Inst (1984) 1.08
A case-control study of multiple myeloma and occupation. Am J Ind Med (1993) 1.04
A multicenter case-control study in Italy on hematolymphopoietic neoplasms and occupation. Epidemiology (2001) 1.04
Mortality among agricultural extension agents. Am J Ind Med (1988) 1.02
Pesticide exposures and multiple myeloma in Iowa men. Cancer Causes Control (1993) 1.00
Cancer risk in farmers: results from a multi-site case-control study in north-eastern Italy. Int J Cancer (1993) 0.96
Occupational risk factors for multiple myeloma among Danish men. Cancer Causes Control (1992) 0.95
Multiple myeloma in Swedish agricultural workers. Int J Epidemiol (1986) 0.93
Risk of multiple myeloma by occupation and industry among men and women: a 24-state death certificate study. J Occup Med (1994) 0.92
Cancer incidence among Finnish farmers, 1979-93. Cancer Causes Control (1997) 0.91
Leukemia and multiple myeloma in farmers. Am J Epidemiol (1971) 0.84
A retrospective cohort study of cancer incidence among New York State Farm Bureau members. Arch Environ Health (1990) 0.83
Incidence and outcome of multiple myeloma in Western Australia, 1960 to 1984. Aust N Z J Med (1988) 0.82
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2004) 4.77
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Bayesian methods for highly correlated exposure data. Epidemiology (2007) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol (2009) 3.07
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol (2009) 2.95
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol (2009) 2.84
Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect (2004) 2.79
Swine workers and swine influenza virus infections. Emerg Infect Dis (2007) 2.74
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Multiple myeloma: diagnosis and treatment. Mayo Clin Proc (2005) 2.62
A quantitative approach for estimating exposure to pesticides in the Agricultural Health Study. Ann Occup Hyg (2002) 2.60
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol (2002) 2.55
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood (2008) 2.49
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
Current therapy for multiple myeloma. Mayo Clin Proc (2002) 2.47
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2002) 2.43
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc (2004) 2.43
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. J Natl Cancer Inst (2009) 2.42
The biobank of the Norwegian Mother and Child Cohort Study: a resource for the next 100 years. Eur J Epidemiol (2006) 2.41
Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. Am J Epidemiol (2003) 2.39
The high cost of cancer drugs and what we can do about it. Mayo Clin Proc (2012) 2.39
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol (2006) 2.38
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37